Targeted therapy in a
narrow sense is anti-HER-2 therapy for HER-2 positive breast cancer patients, with anti-HER-2 drugs such as trastuzumab used in the early adjuvant therapy stage and drugs such as lapatinib used in the late rescue stage. Anti-HER-2 therapy is not recommended for breast cancer patients with T1a tumors and microtumors; anti-HER-2 therapy is recommended for breast cancer patients with T1b or above and young patients with histological grade 3, hormone receptor negative, and small tumors. The specific medication should be combined with clinical practice and guided by the doctor. Targeted therapy aims at the site of tumor occurrence, using drugs that can specifically bind to the site to attack tumor cells accurately and directionally. Compared with traditional radiotherapy and chemotherapy, it has the characteristics of precise localization. Targeted therapy is not suitable for all breast cancer patients. At present, targeted drugs for breast cancer include lapatinib and pertuzumab. Patients with endocrine therapy are prone to develop drug resistance, and Pabol and m-Tor pathway inhibitors play a role in reversing the drug resistance of endocrine therapy.
Specific medication should be combined with clinical practice and guided by the doctor’s face-to-face diagnosis. Targeted drugs for the treatment of breast cancer mainly include the following categories 12:
Macromolecular antibody drugs: such as trastuzumab, pertuzumab, etc. Trastuzumab and pertuzumab are mainly used for adjuvant therapy and first-line treatment of advanced breast cancer.
Small molecule tyrosine kinase inhibitors, such as lapatinib and pirotinib. These drugs are mainly used in the second-line treatment of advanced breast cancer.
CDK4/6 inhibitors: such as Piperacillin, Reboxinil, etc. These drugs are mainly used for the treatment of hormone receptor-positive advanced breast cancer.
Endocrine therapy drugs: such as tamoxifen, anastrozole, letrozole, etc. These drugs inhibit the growth of breast cancer cells by blocking the synthesis or action of estrogen.
Other targeted drugs: bevacizumab, everolimus, etc. Bevacizumab is mainly used to inhibit tumor angiogenesis, while everolimus acts by inhibiting the mTOR pathway.
It should be noted that the selection of targeted drugs should be based on the results of genetic testing of patients to ensure the effectiveness and safety of treatment.
